KStrategy&
@kstrategyand.bsky.social
17 followers
1 following
140 posts
KStrategy& develops digital solutions and helps #healthcare / #pharma companies maximize the value of their discoveries through research and consulting services
Posts
Media
Videos
Starter Packs
KStrategy&
@kstrategyand.bsky.social
· Feb 12
Weekly Roundup - PHARMA - 10 February 2025
🔊Celltrion’s Avtozma Wins FDA Approval for Autoimmune & Inflammatory Diseases Avtozma, an Actemra biosimilar, is approved in both IV and SC forms, backed by a Phase III trial confirming its similarity...
www.linkedin.com
KStrategy&
@kstrategyand.bsky.social
· Feb 12
Weekly Roundup - DIGITAL HEALTH/DTx - 11 February 2025
Highmark Health Expands Access to Stanza, FDA-Cleared Digital Therapy for Fibromyalgia Swing Therapeutics' digital treatment for fibromyalgia, Stanza, has received a positive coverage decision from Hi...
www.linkedin.com
KStrategy&
@kstrategyand.bsky.social
· Feb 12
UWA Researchers Secure $3M to Drive AI-Powered Digital Health Innovations
The University of Western Australia (UWA) continues to solidify its reputation as a leader in digital health innovation, with eight of its researchers securing nearly $3 million in funding through the...
www.linkedin.com
KStrategy&
@kstrategyand.bsky.social
· Feb 3
Weekly Roundup - PHARMA - 3 February 2025
🔊AstraZeneca’s Calquence Wins FDA Approval as First-Line Treatment for Mantle Cell Lymphoma AstraZeneca’s Calquence (acalbrutinib) received FDA approval for first-line mantle cell lymphoma, showing a ...
www.linkedin.com
KStrategy&
@kstrategyand.bsky.social
· Feb 3
AstraZeneca’s Calquence Gains Full Approval for Lymphoma, Faces Medicare Price Negotiations
AstraZeneca has earned full FDA approval for its lymphoma treatment, Calquence, offering a significant step forward in the fight against mantle cell lymphoma (MCL). Originally granted accelerated appr...
www.linkedin.com
KStrategy&
@kstrategyand.bsky.social
· Feb 3
Retro Biosciences and OpenAI Join Forces to Tackle Aging with $1 Billion Investment
San Francisco-based Retro Biosciences, a biotech start-up with a bold vision to extend human life by a decade, is gearing up for a $1 billion funding round to accelerate its ambitious mission. Backed ...
www.linkedin.com
KStrategy&
@kstrategyand.bsky.social
· Jan 31
FDA Approves Johnson & Johnson's SPRAVATO® as the First Monotherapy for Treatment-Resistant Depression in Adults
Johnson & Johnson has just achieved a major breakthrough in the mental health space, with the approval of SPRAVATO® (esketamine) nasal spray as the first and only monotherapy for adults suffering from...
www.linkedin.com
KStrategy&
@kstrategyand.bsky.social
· Jan 29
Tuva Health’s Open-Source Approach to Healthcare Data Wins $5M in Seed Funding
Tuva Health, an open-source healthcare data transformation platform, has officially emerged from stealth with a $5 million seed round and a bold vision to revolutionize the healthcare analytics indust...
www.linkedin.com
KStrategy&
@kstrategyand.bsky.social
· Jan 29
SoriClear by NewLive: South Korea’s Fifth Digital Therapeutic Targets Tinnitus
NewLive, an innovative startup founded by Professor Sang Jae-jun of Korea University Guro Hospital, has recently made waves in the medical field with the approval of its tinnitus treatment tool, SoriC...
www.linkedin.com
KStrategy&
@kstrategyand.bsky.social
· Jan 27
Weekly Roundup - PHARMA - 27 January 2025
🔊AstraZeneca's Calquence Gets Full FDA Approval for Mantle Cell Lymphoma Calquence becomes the first BTK inhibitor approved for first-line treatment of mantle cell lymphoma, offering a 27% progression...
www.linkedin.com
KStrategy&
@kstrategyand.bsky.social
· Jan 27
A New Era in Bladder Cancer Treatment: Pfizer’s Sasanlimab Hits the Mark
Pfizer has unveiled groundbreaking Phase 3 results for its investigational PD-1 inhibitor, sasanlimab, in combination with Bacillus Calmette-Guérin (BCG), a long-standing standard of care for high-ris...
www.linkedin.com
KStrategy&
@kstrategyand.bsky.social
· Jan 27
Lilly Expands Inflammatory Bowel Disease Portfolio with FDA Nod for Omvoh® in Crohn's
Eli Lilly’s Omvoh® (mirikizumab-mrkz) has gained a significant regulatory nod, securing FDA approval for the treatment of moderately to severely active Crohn’s disease in adults. This marks a pivotal ...
www.linkedin.com
KStrategy&
@kstrategyand.bsky.social
· Jan 24
Karolinska Institute’s Digital Physiotherapy App Transforms Stroke Recovery with Nationwide Impact
A breakthrough study from Karolinska Institute is redefining stroke rehabilitation by introducing a fully digital approach to physiotherapy that has proven highly effective and widely accessible. Publ...
www.linkedin.com
KStrategy&
@kstrategyand.bsky.social
· Jan 24
FDA and MFDS Approve ImmunoForge’s Leading Drugs for DMD and CML, Accelerating Clinical Trials
ImmunoForge, a pioneering biotech company, is making significant strides in the treatment of serious medical conditions with the recent approval of two Investigational New Drug (IND) applications by r...
www.linkedin.com
KStrategy&
@kstrategyand.bsky.social
· Jan 23
Cambridge and Cancer Research UK Unveil £10M AI-Powered Cancer Detection Programme
In a groundbreaking effort to revolutionize cancer prevention and detection, Cambridge researchers are spearheading a £10 million initiative that promises to change how cancer is identified and manage...
www.linkedin.com
KStrategy&
@kstrategyand.bsky.social
· Jan 23
Eli Lilly Joins Forces with Scorpion Therapeutics in $2.5 Billion Cancer Drug Deal
Eli Lilly and Co. is making waves in the oncology world with its bold move to acquire Scorpion Therapeutics' experimental PI3K inhibitor for a staggering $2.
www.linkedin.com
KStrategy&
@kstrategyand.bsky.social
· Jan 23
JP Morgan Healthcare Conference: J&J, Eli Lilly, and GSK Spark M&A Revival in 2025
The financial hub of San Francisco buzzed with anticipation as the prestigious JP Morgan Healthcare Conference unfolded, setting the stage for a series of transformative announcements that could resha...
www.linkedin.com
KStrategy&
@kstrategyand.bsky.social
· Jan 23
FDA Approves AstraZeneca and Daiichi Sankyo's Datopotamab Deruxtecan: A Breakthrough for Advanced Breast Cancer
In a groundbreaking advancement for breast cancer treatment, the FDA has granted approval to datopotamab deruxtecan-dlnk, a Trop-2-directed antibody and topoisomerase inhibitor conjugate. Developed co...
www.linkedin.com